InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Bausch + Lomb moved to bolster the eye-care company's pipeline of clinical-stage offerings with the acquisition of Whitecap Biosciences, a firm developing two therapies for potential use in glaucoma ...

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national nonprofit ...

Michael Bromberg is a finance editor with a decade of experience. He is an expert at elucidating complex financial topics in clear, concise language. Michael received a Bachelor of Arts in ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders ...

Evercore ISI lowered the firm’s price target on Bausch + Lomb (BLCO) to $22 from $25 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman ...

Egg production in the U.S. dropped 4% in November as the price of eggs and cases of bird flu continue to rise across the country, according to a report from the United States Department of ...

Cities across the U.S. marked the new year with different iconic "drops." Happy New Year from Early Today. Jan. 1, 2025 ...